Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2708342 | 0.84 | PIM1 (0.49) | ESR1ESR2HSP90AA1PIM1KDM4E | |
| SCHEMBL13244919 | 0.81 | ESR1 (0.39) | ESR1ESR2HSP90AA1SCD5PIM1 | |
| SCHEMBL2137945 | 0.79 | ESR1 (0.61) | ESR1ESR2HSP90AA1KDM4EALDH1A1 | |
| SCHEMBL1530408 | 0.76 | BRD4 (0.45) | ESR1ESR2KDM4EALDH1A1LMNA | |
| SCHEMBL20393976 | 0.76 | ACHE (0.39) | ESR1ESR2HSP90AA1SCD5KDM4E | |
| SCHEMBL1942334 | 0.76 | IDO1 (0.46) | ESR1ESR2HSP90AA1SCD5KDM4E | |
| SCHEMBL1836503 | 0.76 | ALDH1A1 (0.49) | ESR1ESR2HSP90AA1ALDH1A1 | |
| SCHEMBL8290795 | 0.76 | ESR1 (0.41) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5514251 | 0.76 | ACHE (0.41) | ESR1ESR2HSP90AA1ACHE | |
| SCHEMBL1101176 | 0.76 | ESR1 (0.45) | ESR1ESR2HSP90AA1SMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070054942-A1 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| US-7166725-B2 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166725-B2 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166725-B2 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1711478-A2 | BENZO [D]ISOXAZOL-3-OL DAAO INHIBITORS | Sepracor Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005066143-A2 | BENZO[D]ISOXAZOL-3-OL DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066143-A2 | BENZO[D]ISOXAZOL-3-OL DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRM1 | ESR1 987/4885ESR2 901/4885HSP90AA1 2799/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | ESR1 4351/4885ESR2 3556/4885HSP90AA1 1203/4885 |
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | DDO, DAO, CACNA1S | ESR1 2250/4885ESR2 3052/4885HSP90AA1 3107/4885 |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | CNKSR1, MAPK1, MAPK7 | ESR1 4545/4885ESR2 2672/4885HSP90AA1 139/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | ESR1 2684/4885ESR2 1946/4885HSP90AA1 2522/4885 |
| US-20070054942-A1 | Fused heteroaryl derivatives and their use as p38 kinase inhibitors | MAPK1, MAPK7, MAPKAPK2 | ESR1 4288/4885ESR2 1843/4885HSP90AA1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.